
The fund will invest about $150 million to acquire about 60% stake in the company, ET first reported in November. The deal, expected to value the company at $250 million, will see the exit of existing investor Everstone Capital and a handful of HNIs. Everstone held about 35% stake in the company.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3seLC9r
via
IFTTT
0 comments:
Post a Comment